June 2018

Promising Umbralisib Combinations Tested in Non-Hodgkin Lymphoma Subtypes

June 26, 2018

Clinical Trials in Progress

The phase IIb UNITY-NHL clinical trial (NCT02793583) aims to determine whether the novel drug umbralisib (TGR-1202) could be used as monotherapy or in combination with other drugs to treat patients with relapsed/refractory non-Hodgkin lymphoma (NHL).

Trial Combines Selinexor With Standard Therapy in Multiple Myeloma

June 21, 2018

Clinical Trials in Progress

Selinexor (KPT-330), a promising drug that retards cell malignancy by blocking the transport of tumor-suppressor proteins out of the cell nucleus, is under investigation as combination therapy in heavily pretreated patients with relapsed/refractory multiple myeloma.

Nurse Trust Among Patients With Ports

June 20, 2018

Partner Perspectives

Research has shown that pain and anxiety are related to port access, so a need exists to capture patients’ feelings and emotions related to living with a port, as well as effective nursing interventions aimed at addressing those patient experiences.